CRISPR Therapeutics AG (CRSP)
NGM – Real Time Price. Currency in USD
54.08
+0.01 (0.02%)
Market open: Aug 12, 2026, 10:07 AM EDT
53.80
-0.27 (-0.50%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
54.08
+0.01 (0.02%)
Market open: Aug 12, 2026, 10:07 AM EDT
53.80
-0.27 (-0.50%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
No Data
There are no news for this stock.
Total debt $783.7M significantly exceeds cash reserves ($291.7M), raising financial stability concerns
Total current assets $2.4B exceed Total current liabilities $132.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.4) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$84.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 17.85 | 6.05 | 10 | |
| Quick ratio | 17.85 | 5.63 | 10 | |
| Debt to Equity | 0.45 | 0.30 | 7.0 | |
| Debt to Assets | 0.30 | 1.04 | 7.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1M | 371M | 37M | 4M | 13M |
| Gross Profit | -133M | 221M | -92M | -229M | -202M |
| Operating Income | -673M | -223M | -467M | -568M | -532M |
| Net Income | -650M | -154M | -366M | -582M | -451M |
| EBITDA | -649M | -203M | -447M | -549M | -513M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 1481.28 | 9.68 | 8.0 |
| Next quarter | 1533.52 | 16.17 | 9.5 |
| Current year | 983.98 | 31.12 | 10 |
| Next year | 287.5 | 26.04 | 10 |
| Weighted average score | 9.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 598.29 | 25.85 | 26.56 | 23.08 | 10 |
| Y/Y | 1041.37 | 56.29 | 60.83 | 26.19 | 10 |
| 3y average | 10234.99 | -40.27 | -31.98 | -14.44 | 3.3 |
| 5y average | 31552.01 | -36.94 | -36.99 | 3.65 | 4.0 |
| Weighted average score | 6.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |